Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 10/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950945 | 0.85 | BDKRB1 (0.35) | MAP3K14BDKRB1PTGDR2 | |
| SCHEMBL5950949 | 0.85 | BDKRB1 (0.35) | MAP3K14BDKRB1PTGDR2 | |
| SCHEMBL14272028 | 0.73 | — | — | |
| SCHEMBL14307705 | 0.72 | HTR1D (0.36) | P2RX7 | |
| SCHEMBL12316627 | 0.70 | MAP3K14 (0.57) | MAP3K14PTGDR2 | |
| SCHEMBL12316538 | 0.70 | MAP3K14 (0.57) | MAP3K14 | |
| SCHEMBL12316626 | 0.67 | MAP3K14 (0.49) | MAP3K14PTGDR2 | |
| SCHEMBL12316632 | 0.67 | MAP3K14 (0.49) | MAP3K14 | |
| SCHEMBL4526156 | 0.67 | SLC8A1 (0.35) | — | |
| SCHEMBL13092731 | 0.66 | MAP3K14 (0.54) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | disclosed |
| US-7393852-B2 | Piperazine derivatives and methods of use | AMGEN INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1656355-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1856074-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | Amgen, Inc (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1799637-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | Amgen, Inc (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060111347-A1 | Substituted sulfones and methods of use | AMGEN INC. (US) | 2006-05-25 | — | — | US | disclosed |
| EP-1656355-A2 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006041888-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006036664-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005061467-A2 | PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | AMGEN INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | MAP3K14 1509/4885BDKRB1 259/4885P2RX7 17/4885 |
| US-20060111347-A1 | Substituted sulfones and methods of use | SULT2A1, STS, SULT1A1 | MAP3K14 1736/4885BDKRB1 419/4885P2RX7 313/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | MAP3K14 1441/4885BDKRB1 533/4885P2RX7 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.